Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss

Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.

For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Aon names interim CFO as Edmund Reese exits the firm